title: Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats.
abstract: Prostaglandin E2 (PGE2) has been shown to stimulate both bone resorption and formation in experimental animals, leading to augmentation of trabecular and cortical bone. The amino bisphosphonate alendronate (ALN) is a potent inhibitor of bone resorption. The objectives of this study were to examine if PGE2 stimulation of bone formation was dependent on bone resorption and if the bone accrued as a result of PGE2 treatment contributed to bone strength. The 48 female Sprague-Dawley rats were assigned to six groups as follows: five groups (8/group) were ovariectomized at the age of 6 months. One group was sacrificed 2 months later to establish baseline conditions, and four groups were treated for 25 days with (1) vehicle, (2) PGE2 at 3 mg/kg/day, (3) ALN sc at 0.8 micrograms/kg/day, and (4) PGE2 + ALN at the respective doses. The sixth group served as nonovariectomized untreated controls. Histomorphometric analysis of 6-10 microns thick tibial sections after in vivo fluorochrome double labeling showed that treatment with PGE2 alone increased endocortical mineral apposition rate and bone formation rate, stimulated production of bone trabeculae in the marrow cavity, and increased cortical porosity. Combined ALN + PGE2 treatment prevented the resorption induced by PGE2 but not the stimulation of bone formation on endocortical and periosteal surfaces and resulted in a significant increase in cortical thickness. Consistent with these observations, the femoral midshaft tested to failure in three-point bending showed a significant increase in strength in the PGE2 + ALN group (181 +/- 15 N) compared to time 0 controls (145 +/- 23 N) or to the ovariectomized vehicle-treated group (141 +/- 28 N).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Orthopaedic Surgery, Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts.
authors.forename: D B
authors.initials: DB
authors.lastname: Lauritzen
authors.forename: R
authors.initials: R
authors.lastname: Balena
authors.forename: M
authors.initials: M
authors.lastname: Shea
authors.forename: J G
authors.initials: JG
authors.lastname: Seedor
authors.forename: A
authors.initials: A
authors.lastname: Markatos
authors.forename: H M
authors.initials: HM
authors.lastname: Le
authors.forename: B C
authors.initials: BC
authors.lastname: Toolan
authors.forename: E R
authors.initials: ER
authors.lastname: Myers
authors.forename: G A
authors.initials: GA
authors.lastname: Rodan
authors.forename: W C
authors.initials: WC
authors.lastname: Hayes
mesh_terms: D019386:Alendronate; D000818:Animals; D001696:Biomechanical Phenomena; D015519:Bone Density / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects*; D001862:Bone Resorption; D001842:Bone and Bones / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D015232:Dinoprostone / Q000494:pharmacology*; D004164:Diphosphonates / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D005269:Femur; D006614:Hindlimb; D008159:Lumbar Vertebrae; D010052:Ovariectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D012984:Software
chemical_list: D004164:Diphosphonates; D015232:Dinoprostone; D019386:Alendronate